10-QPeriod: Q2 FY2016

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2016

Filed August 2, 2016For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported solid revenue growth in the second quarter of 2016, with total revenue increasing by 12.9% year-over-year to $466.6 million. This growth was primarily driven by the Companion Animal Group (CAG) segment, which saw a 13.8% increase in revenue, largely due to strong performance in recurring diagnostics revenue, including reference laboratory services and consumables. The company demonstrated healthy operating income growth of 18.0%, reaching $104.2 million, with an operating margin of 22.3%. Net income attributable to stockholders also saw a significant increase, up 18.1% to $67.2 million, leading to diluted earnings per share of $0.74, an increase from $0.60 in the prior year. Financially, IDEXX maintained a strong liquidity position with cash and cash equivalents and marketable securities totaling $370.2 million. The company's cash flow from operations was robust, providing $134.1 million in the first six months of the year. While the company continued its share repurchase program, the pace moderated compared to the previous year, indicating a balanced approach to capital allocation. The company's outlook remains positive, with continued investment in growth areas and a focus on operational efficiency.

Financial Statements
Beta

Key Highlights

  • 1Total revenue increased by 12.9% to $466.6 million for the three months ended June 30, 2016, compared to $413.3 million in the prior year.
  • 2Companion Animal Group (CAG) revenue grew by 13.8% to $400.2 million, driven by strong demand for recurring diagnostics services and consumables.
  • 3Operating income rose by 18.0% to $104.2 million, with operating margin improving to 22.3% from 21.4% in the prior year.
  • 4Net income attributable to IDEXX stockholders increased by 18.1% to $67.2 million.
  • 5Diluted earnings per share (EPS) improved to $0.74 from $0.60 in the same period last year.
  • 6The company maintained a strong balance sheet with $370.2 million in cash, cash equivalents, and marketable securities as of June 30, 2016.
  • 7Cash flow from operating activities for the six months ended June 30, 2016, was $134.1 million, a significant increase from $65.5 million in the prior year.

Frequently Asked Questions

The primary growth driver is the Companion Animal Group (CAG) segment, which accounts for the majority of revenue and showed robust growth, particularly in its recurring diagnostics revenue streams like reference laboratory services and consumables. This indicates strong underlying demand from veterinary practices.

The strengthening U.S. dollar had a negative impact on reported revenue, decreasing total company revenue by approximately $2.8 million for the three months ended June 30, 2016. While hedging activities partially offset this, lower relative hedging gains compared to the prior year also impacted gross profit margins. The company estimated a 10% strengthening of the U.S. dollar could reduce operating income by approximately $6 million for the remainder of 2016.

IDEXX Laboratories maintains a strong liquidity position with $370.2 million in cash, cash equivalents, and marketable securities as of June 30, 2016, and significant availability under its credit facility. The company believes these resources, along with cash generated from operations, will be sufficient to fund operations, capital expenditures, and anticipated growth needs for the next twelve months and the foreseeable future.

The filing does not indicate any material acquisitions or divestitures during the period ended June 30, 2016. The 'Other' segment, however, includes the OPTI Medical business, where the company discontinued product development activities and recorded an impairment charge due to unfavorable trends.